Gilead Buys Out Rights to Cancer Therapy From Jounce for $67 Million ...Middle East

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday. Reuters Health Information

Hence then, the article about gilead buys out rights to cancer therapy from jounce for 67 million was published today ( Wednesday 28/12/2022 - 11:57 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gilead Buys Out Rights to Cancer Therapy From Jounce for $67 Million )

Also on site :

• Aura AI Assistant for Unreal Engine Launches: VR Studio Ships Game in Half the Time with New Agent Capabilities
• Man accused of placing pipe bombs near GOP and Democratic headquarters in Washington to remain in jail pending trial
• Driver dies after plow truck goes off the road in Steuben County